Catherine Bollard

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Catherine Bollard sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).

14 total trials 2 currently recruiting 7 completed early-phase tilt top decile by trial count

Catherine Bollard: 14 sponsored US clinical trials, 2 recruiting.

Catherine Bollard sponsors 14 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 7 completed. 0 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Refractory Viral Infections, with 1 trials.

Top-decile sponsor footprint

Catherine Bollard ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

14 total, page 1 of 1

RECRUITING Phase 1

Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis

NCT03594981
RECRUITING Phase 1

Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies

NCT02203903
ACTIVE NOT RECRUITING Phase 2

HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903

NCT04975698
ACTIVE NOT RECRUITING Phase 1

Mesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP)

NCT04236479
ACTIVE NOT RECRUITING Phase 1

Evaluate the Safety, Immunologic, and Virologic Responses of Donor Derived (DD) HIV-Specific T-cells (HST) in HIV-infected Individuals Following Allogeneic Bone Marrow Transplantation (alloRESIST)

NCT04248192
ACTIVE NOT RECRUITING Phase 1

Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma

NCT03843294
ACTIVE NOT RECRUITING Phase 1

Multi-antigen T Cell Infusion Against Neuro-oncologic Disease

NCT03652545
COMPLETED Phase 1

HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected Individuals

NCT03485963
COMPLETED Phase 1

Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease

NCT02150551
COMPLETED Phase 1

Haploidentical Hematopoietic Stem Cell Transplantation

NCT02165007
COMPLETED Phase 1

Allogeneic Virus-specific T Cell Lines (VSTs)

NCT02510417
COMPLETED Phase 1

Multivirus-specific Cytotoxic T Lymphocytes (mCTL)

NCT02510404
COMPLETED Phase 1

Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)

NCT01945814
COMPLETED Phase 1

Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma

NCT01956084

Phase Distribution

PhaseTrial count
Phase 1 13
Phase 2 1

Therapeutic Areas

Refractory Viral Infections 1
HIV Associated Lymphoma 1
HIV-Infected Individuals 1
Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS 1
Congenital Heart Disease (CHD) 1
Viral Infection 1
Hodgkin Lymphoma 1
Brain Tumor 1
HIV Infections 1
Diffuse Large B Cell Lymphoma 1

What is open in the Catherine Bollard pipeline

2 recruiting of 14 indexed (14% open); 7 completed (50%).

Phase mix: 0 late (III/IV) vs 14 early (I/II) (early-phase heavy).

Top condition: Refractory Viral Infections (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Catherine Bollard: open-pipeline peers nationwide

Peers matched on 14 registered trials and 14% open enrollment, not the therapeutic-area sidebar.

Catherine Bollard sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%5%10%15%20% Total trials Recruiting share Catherine Bollard3-C Institute for Social DevelopmentAbbott Medical OpticsAbbott RDx CardiometabolicAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAAcademic and Community Cancer Research UnitedAdaptive BiotechnologiesAgelessRxAlaska Blind Child Discovery
Catherine Bollard sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Catherine Bollard sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 14 trials (± recruiting share)

Sponsors near 14% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Catherine Bollard page

14 registered trials is a research-attention snapshot, not an endorsement of Catherine Bollard or any single study.

  • 2 of Catherine Bollard's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Refractory Viral Infections is the condition Catherine Bollard studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Refractory Viral Infections trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Catherine Bollard pipeline card: 14 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.